格隆汇3月30日丨中远海发(601866.SH)发布2025年年报显示，公司全年实现营业收入252.01亿元，同比 下滑8.78%；归母净利润16.09亿元，同比下滑4.54%；扣非归母净利润15.44亿元，同比增长10.76%。对 全体股东10派0.15元。 ...

Core Viewpoint - China Duty Free Group (01880.HK) reported a revenue decrease of 4.92% year-on-year to RMB 53.694 billion for the fiscal year ending December 31, 2025, with a profit attributable to equity shareholders of RMB 3.644 billion and earnings per share of RMB 1.7613 [1] Group 1: Financial Performance - Revenue for the fiscal year is projected to decline by 4.92% to RMB 53.694 billion [1] - Profit attributable to equity shareholders is expected to be RMB 3.644 billion [1] - Earnings per share is reported at RMB 1.7613 [1] Group 2: Strategic Initiatives - The company is leveraging the historical opportunity of Hainan's full island closure operations by focusing on scene innovation, service upgrades, and supply chain assurance [1] - Efforts are being made to deepen the integration of "duty-free + cultural tourism," creating immersive experiences and actively introducing new products and flagship stores [1] - Collaborations with over 10 popular IPs, including Pop Mart and Disney, are aimed at driving traffic and conversion through partnerships with hotels, new media, and cultural events [1] Group 3: Market Positioning - The company is contributing to the construction of Hainan as an international tourism consumption center and free trade port [1] - Government consumption vouchers are being utilized to stabilize and boost sales in the Hainan region, resulting in an increase in market share for the offshore duty-free market [1] - The company is committed to "integrity in operation and quality service," advancing service standardization and achieving ISO certification in three management systems [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) reported a revenue of 283.58 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 3.03% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 24.52 billion RMB, an increase of 3.33% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 259.06 billion RMB, growing by 3.00% year-on-year [1] Profit Analysis - The net profit attributable to shareholders reached 5.73 billion RMB, marking a significant increase of 25.74% year-on-year, primarily due to a one-time special gain from the change in accounting treatment of Hutchison Whampoa from an equity method to a subsidiary [1] - After excluding one-time special gains and losses, the net profit attributable to shareholders was 4.72 billion RMB, which represents a decline of 5.56% year-on-year [1] Segment Contribution - The industrial segment contributed a profit of 2.04 billion RMB [1] - The commercial segment contributed a profit of 3.46 billion RMB [1] - Profits from major associated enterprises amounted to 325 million RMB [1]

Group 1 - The core point of the article is that Schroders PLC has increased its stake in Kailaiying (06821.HK) by purchasing 88,500 shares at an average price of HKD 79.0296 per share, totaling approximately HKD 6.9941 million [1] - Following this acquisition, Schroders PLC's total shareholding in Kailaiying has risen to 5.6214 million shares, increasing its ownership percentage from 19.88% to 20.20% [1]

Core Viewpoint - The company, Tigermed (03347.HK), is expanding its international business and plans to engage in foreign exchange hedging to mitigate foreign currency exchange rate risks while ensuring stable operations [1] Group 1: Foreign Exchange Hedging - The company and its subsidiaries intend to conduct foreign exchange hedging based on actual business needs, avoiding speculative foreign exchange trading [1] - The maximum contract value held on any trading day is expected to not exceed RMB 300 million or its equivalent in foreign currency [1] - The margin and premium used for trading will not exceed 50% of the company's most recent audited net profit [1] Group 2: Transaction Limits - At any given time, the transaction amount, including related amounts from the profits of the aforementioned trades, will not exceed RMB 300 million or its equivalent in foreign currency [1]

减持后，BlackRock, Inc.最新持好仓数目为490,212,875股，持好仓比例由6.45%下降至5.89%。 格隆汇3月30日丨根据联交所最新权益披露资料显示，2026年3月24日，民生银行(01988.HK)遭 BlackRock, Inc.在场内以每股均价3.8259港元减持好仓4617.63万股，涉资约1.77亿港元。 ...

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) reported a revenue of 283.58 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 3.03% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 24.52 billion RMB, an increase of 3.33% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 259.06 billion RMB, growing by 3.00% year-on-year [1] Profit Analysis - The net profit attributable to shareholders reached 5.73 billion RMB, marking a significant increase of 25.74% year-on-year, primarily due to a one-time special gain from the change in accounting treatment of Hutchison Whampoa from equity method to subsidiary accounting [1] - After excluding one-time special gains and losses, the net profit attributable to shareholders was 4.72 billion RMB, which represents a decline of 5.56% year-on-year [1] Segment Contribution - The industrial segment contributed a profit of 2.04 billion RMB [1] - The commercial segment contributed a profit of 3.46 billion RMB [1] - Profits from major associated enterprises amounted to 325 million RMB [1]

Group 1 - The core point of the article is that China Ping An Insurance (Group) Co., Ltd. has increased its stake in China Pacific Insurance (02601.HK) by purchasing 3.1044 million shares at an average price of HKD 32.3919 per share, totaling approximately HKD 101 million [1] - Following the acquisition, China Ping An's total shareholding in China Pacific Insurance has risen to 335,393,200 shares, increasing its ownership percentage from 11.97% to 12.08% [1]

格隆汇3月30日丨金隅集团(02009.HK)发布2025年度业绩。营业收入为人民币911.13亿元，较2024年减 少约17.7%。净亏损约为人民币15.07亿元，较2024年的净亏损减少1.8%。归属于母公司股东的净亏损约 为人民币10.1亿元，较2024年的归属于母公司股东的净亏损增加约81.8%，归属于母公司股东的基本每 股亏损(未扣除其他权益工具利息)约为人民币0.09元，董事会建议派发末期股息每股人民币0.05元(税 前)。 2025年，公司全面落实「一双双三三统」」工作要求，紧扣「双质量发展突破年」主题，公司上下凝心 聚力、承压奋进，服服内外部境境杂多变变、市回回不不及预期等变重不利因素影响，交出一份来之不 易的答卷。 ...

格隆汇3月30日丨神冠控股(00829.HK)公告，截至2025年12月31日止年度业绩，收入由上年度约人民币 10.17亿元增加约0.6%至年度约人民币10.23亿元。集团于年度的母公司拥有人应占亏损约为人民币6980 万元。上年度则为母公司拥有人应占盈利约人民币2670万元。 为释放营运资金以及避免进一步增加存货撇销及拨备，集团于本年度下半年采用薄利多销的政策，尽力 促销旧工艺产品以及和过去年度新产品和设备改造试制有关的成品。 ...